Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MIDRIXNEO-LUNG
- Development stage
- Phase 1
- Lead developer
- Ghent University Hospital
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies
- Administration
- Intravenous
01
Overview
MIDRIXNEO-LUNG is an autologous dendritic cell vaccine designed for the treatment of non-small cell lung cancer (NSCLC), including metastatic and resected cases. The therapy involves isolating dendritic cells from the patient, loading them ex vivo with messenger RNA (mRNA) encoding tumor-specific neoantigens predicted from the individual patient's tumor mutanome, and then administering these activated cells intravenously back to the patient. The goal is to stimulate a robust immune response specifically targeting cancer cells expressing these neoantigens. It has been evaluated in Phase 1 clinical trials to establish safety, immunogenicity, and maximal tolerated dose in NSCLC patients. Developed by Ghent University Hospital, this personalized immunotherapy aims to overcome resistance seen with other immune checkpoint inhibitors in NSCLC.
- Other names
- antigen-specific delayed-type hypersensitivity-University Hospital, Ghent-non-small cell lung cancerAntigen-specific DTHMIDRIXNEO-LUNG DCsAutologous neoantigen-targeted dendritic cell immunotherapy
Beyond the preview
Go deeper on MIDRIXNEO-LUNG.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MIDRIXNEO-LUNG.